DOCSLIB.ORG

207145Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
207145Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207145Orig1s000 MEDICAL REVIEW(S) Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) CLINICAL REVIEW Application Type NDA Application Number 207145 Priority or Standard Standard Submit Date 9/21/16 Received Date 9/21/16 PDUFA Goal Date 3/21/17 Division / Office DNP/ODE 1 Reviewer Name Leonard P. Kapcala, M.D. Review Completion Date 2/7/17 Established Name SAFINAMIDE (Proposed) Trade Name XADAGO Therapeutic Class Monoamine Oxidase B Inhibitor Applicant Newron Formulation(s) Tablet Dosing Regimen Once daily orally Indication(s) Treatment of signs and symptoms of Parkinson's disease Intended Population(s) Patients with early and advanced Parkinson's disease 1 Reference ID: 4071416 Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 4 1.1 Recommendation on Regulatory Action ............................................................. 4 1.2 Risk Benefit Assessment .................................................................................... 4 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 5 1.4 Recommendations for Postmarket Requirements and Commitments ................ 5 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 5 2.1 Product Information (Based Upon Sponsor Summary) ....................................... 5 2.2 Other Relevant Background Information ............................................................ 6 3 SAFETY UPDATE .................................................................................................... 7 2 Reference ID: 4071416 Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) Table of Tables Table 1 Serious Adverse Events in Ongoing Double-Blind Japanese Study ME2125-3 .................................................................................................. 11 Table 2 Serious Adverse Events in an Ongoing Open-label, Long-term, Japanese study – ME2125-4 .................................................................... 13 Table 3 Estimation of Patients Treated with Xadago in EU Countries Based on Volume of Blister Pack Sales .................................................................. 14 Table 4 Listing of Spontaneously Reported Post-Marketing Serious Adverse Events ....................................................................................................... 15 3 Reference ID: 4071416 Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) 1 Recommendations/Risk Benefit Assessment 1.1 Recommendation on Regulatory Action • I recommend approval of this NDA for adjunctive treatment with levodopa/carbidopa in patients with Parkinson’s disease to reduce “off” episodes. 1.2 Risk Benefit Assessment • It is my opinion that this risk benefit assessment for safinamide supports the approval of safinamide for treatment of signs and symptoms of patients experiencing “off” episodes and taking concomitant levodopa/carbidopa (i.e., patients with advanced Parkinson's disease). The two pivotal trials (Studies 16 and SETTLE) conducted for advanced Parkinson's disease were positive and demonstrated adequate efficacy of safinamide. The safety profile of safinamide for treating this population was acceptable. My previous review (entered in DARRTS on 3/27/16) includes my detailed assessment risk benefit assessment of the efficacy and safety of safinamide. • After completing my review of the sponsor’s Safety Update, I find the information did not suggest any, new or significant adverse reactions that would change my impression of the safety profile for safinamide or my recommendation to approve safinamide as a safe and effective drug. • I do, however, recommend that a new safety finding discovered in my review of this Safety Update be described in the label. Based upon my review of postmarket case 201600064DEU, I believe that hypersensitivity to safinamide should be described in the label as a Contraindication. The adverse reaction of hypersensitivity has the potential being a medically serious event, with potentially a fatal outcome. I conclude that there is a quite reasonable probability that safinamide caused this hypersensitivity reaction and that this hypersensitivity reaction recurred upon rechallenge with safinamide. • I also recommend that the safinamide label should include additional information regarding taking safinamide with two drugs (i.e., linezolid and isoniazid-INH) with monoamine oxidase (MAO) inhibitory activity. During our review of the sponsor’s Complete Response re-submission, we became aware that two antimicrobial drugs (i.e., linezolid and isoniazid) have MAO inhibitory activity. Linezolid is a reversible, nonselective MAO inhibitor which is indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ; Community-acquired pneumonia; Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis; Uncomplicated skin and skin structure infections; and Vancomycin-resistant Enterococcus faecium infections for a treatment period ranging between 10-28 days. Oral 4 Reference ID: 4071416 Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) tyramine challenge testing with linezolid has shown an increase in tyramine sensitivity but the label does not require dietary tyramine restriction. However, concomitant use of an MAO inhibitor is contraindicated in the linezolid label. The INH label notes that it has some MAO inhibiting activity, and that an interaction with tyramine-containing foods (cheese, red wine) may occur when taking INH. However, the INH label does not require dietary tyramine restriction nor does it contraindicate concomitant use of MAO inhibitors. A review of the published literature did not find results from any formal tyramine challenge testing. In view of this new information, I recommend that the safinamide label contraindicate the use of linezolid because the linezolid label notes that it is an MAO inhibitor and the safinamide label contraindicates drugs (selective or nonselective) which are MAO inhibitors. Adding this contraindication in the safinamide label would make both labels consistent with each other relative to contraindicating concomitant MAO inhibitors with the use of safinamide or linezolid. I also recommend that safinamide label describes in the Drug Interactions section of the label that because INH has some MAO inhibitory activity, that patients taking safinamide together with INH could possibly experience a hypertensive reaction when ingesting tyramine containing food or drink. Patients taking safinamide and INH should be monitored for such a hypertensive reaction. Because the precise quantitative extent of MAO inhibition from INH is not clear, I do not believe that a contraindication for INH is necessary. 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies • I do not have any recommendations for the postmarket risk evaluation and mitigation strategies for safinamide. 1.4 Recommendations for Postmarket Requirements and Commitments • I do not have any recommendations for postmarket requirements or commitments for safinamide. 2 Introduction and Regulatory Background 2.1 Product Information (Based Upon Sponsor Summary) Safinamide, an alpha-aminoamide derivative is structurally unrelated to any other drug for treatment of Parkinson’s disease (PD), but is related to milacemide, a glycine prodrug. Safinamide may have multiple mechanisms of action. The sponsor describes properties such as state-dependently inhibits voltage-gated sodium channels (IC50:1.6-4.9 μM for different subtypes), and at higher concentrations it inhibits calcium channels. The expected physiological 5 Reference ID: 4071416 Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) effect is the modulation of the hyper-active neurons and the consequent regulation of the neurotransmitter release: safinamide reduces the stimulated release of glutamate (~0.6 μM) without affecting basal glutamate levels. Safinamide is also a reversible and selective Monoamine Oxidase B (MAO-B) inhibitor (IC50 79-98nM: >1000-fold selective over MAO-A). It also binds at the WIN 35,428 site of the dopamine transporter (DAT) with IC50 of 8.8 μM and displaces the serotonin transporter (SERT) ligand citalopram from its binding with IC50 of 5.6 μM. leading to dopamine and the serotonin uptake inhibition in brain synaptosomes with IC50s of 12.5 and 21 μM, respectively. Safinamide enters the brain, and in animal models of PD has shown both dopaminergic benefits (increased brain dopamine content; extended efficacy of a given dose of L-dopa on motor symptoms) and non-dopaminergic effects (reduced L-dopa induced dyskinesia) associated with plasma safinamide levels corresponding to therapeutic doses in clinical trials. The sponsor also notes that results of some studies in preclinical models of PD and other CNS diseases suggest the possibility that safinamide may have a neuroprotective effect. The initial non-clinical and clinical programs were performed by the Sponsor (Newron). In 2006 Merck-Serono acquired the exclusive worldwide rights to further develop, manufacture and commercialize safinamide. In October 2011, Merck-Serono announced their decision to discontinue the co-development agreement with Newron.
Load more

Recommended publications
  • Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions With
    DMD Fast Forward. Published on November 15, 2018 as DOI: 10.1124/dmd.118.084905 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 84905 Title Mechanisms and Clinical Significance of Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017 Jingjing Yu, Ichiko D. Petrie, René H. Levy, and Isabelle Ragueneau-Majlessi Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA (J.Y., I.P., R.H.L. I.R-M.) Downloaded from dmd.aspetjournals.org at ASPET Journals on October 3, 2021 1 DMD Fast Forward. Published on November 15, 2018 as DOI: 10.1124/dmd.118.084905 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 84905 Running Title Page a) Running title: A review of clinical DDIs in 2017 NDAs b) Corresponding author: Jingjing Yu, Drug Interaction Database (DIDB) Program, Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, Phone: 206.221.2856, Fax: 206.543.3204, E-mail: [email protected] c) Number of text pages: 18 Number of tables: 2 Downloaded from Number of figures: 2 Number of references: 38 Number of words in the Abstract: 242 dmd.aspetjournals.org Number of words in the Introduction: 227 Number of words in the Discussion: 619 d) Abbreviations: at ASPET Journals on October 3, 2021 AUC, area under the time-plasma concentration curve; BCRP, breast cancer resistance protein; Cmax, maximum plasma
    [Show full text]
  • Seizure Disorders and Commercial Motor Vehicle Driver Safety (Comprehensive Review)
    Evidence Report: Seizure Disorders and Commercial Motor Vehicle Driver Safety (Comprehensive Review) Presented to Federal Motor Carrier Safety Administration November 30, 2007 Prepared for Prepared by MANILA Consulting Group, Inc. ECRI 1420 Beverly Road, Suite 220 5200 Butler Pike McLean, VA 22101 Plymouth Meeting, PA 19462 This report is comprised of research conducted to analyze the impact of Seizure Disorders on Commercial Motor Vehicle Driver Safety. Federal Motor Carrier Safety Administration considers evidence, expert recommendations, and other data, however, all proposed changes to current standards and guidance (guidelines) will be subject to public-notice-and-comment and regulatory processes. FMCSA Evidence Report: Seizure Disorders and Commercial Motor Vehicle Driver Safety 11/30/2007 Policy Statement This evidence report was prepared by ECRI under subcontract to MANILA Consulting Group, Inc., which holds prime Contract No: GS-10F-0177N/DTMC75-06-F-00039 with the Department of Transportation’s Federal Motor Carrier Safety Administration. ECRI is an independent, nonprofit health services research agency and a Collaborating Center for Health Technology Assessment of the World Health Organization. ECRI has been designated an Evidence-based Practice Center (EPC) by the United States Agency for Healthcare Research and Quality. ECRI’s mission is to provide information and technical assistance to the healthcare community worldwide to support safe and cost-effective patient care. The results of ECRI’s research and experience are available through its publications, information systems, databases, technical assistance programs, laboratory services, seminars, and fellowships. The purpose of this evidence report is to provide information regarding the current state of knowledge on this topic.
    [Show full text]
  • Novel Neuroprotective Compunds for Use in Parkinson's Disease
    Novel neuroprotective compounds for use in Parkinson’s disease A thesis submitted to Kent State University in partial Fulfillment of the requirements for the Degree of Master of Science By Ahmed Shubbar December, 2013 Thesis written by Ahmed Shubbar B.S., University of Kufa, 2009 M.S., Kent State University, 2013 Approved by ______________________Werner Geldenhuys ____, Chair, Master’s Thesis Committee __________________________,Altaf Darvesh Member, Master’s Thesis Committee __________________________,Richard Carroll Member, Master’s Thesis Committee ___Eric_______________________ Mintz , Director, School of Biomedical Sciences ___Janis_______________________ Crowther , Dean, College of Arts and Sciences ii Table of Contents List of figures…………………………………………………………………………………..v List of tables……………………………………………………………………………………vi Acknowledgments.…………………………………………………………………………….vii Chapter 1: Introduction ..................................................................................... 1 1.1 Parkinson’s disease .............................................................................................. 1 1.2 Monoamine Oxidases ........................................................................................... 3 1.3 Monoamine Oxidase-B structure ........................................................................... 8 1.4 Structural differences between MAO-B and MAO-A .............................................13 1.5 Mechanism of oxidative deamination catalyzed by Monoamine Oxidases ............15 1 .6 Neuroprotective effects
    [Show full text]
  • Therapy for Movement Disorders
    Cynthia Comella, MD, FAAN Rush University Medical Center Chicago, IL TREATMENT OF MOTOR SYMPTOMS IN PARKINSON DISEASE Disclosures . Compensation/honoraria for services as a consultant or an advisory committee member: Acadia, Aeon, Allergan, Inc; Impax Pharmaceuticals; Ipsen Biopharmaceuticals, Inc; Medtronic Inc.; Merz Pharmaceuticals; Neurocrine. Royalties: Cambridge, Humana Press; Wolters Kluwer Objectives Treatment of PD . Available treatments for motor PD Treatment of motor symptoms Treatment of motor complications Motor fluctuations Dyskinesia . Overview new therapies in clinical trial Not my objectives Before I came here I was confused about this subject. Having listened to your lecture I am still confused. But on a higher level. Enrico Fermi PD motor symptoms: Therapeutic targets Oertel W, Shulz JB. J Neurochem 2016 . No effective neuroprotective agent . Monotherapy (Efficacious) Levodopa Dopamine agonists: (pramipexole, ropinirole, rotigotine) MAO-B inhibitors: (selegiline, rasagiline) Amantadine (likely) . Motor fluctuations (Efficacious) Efficacious: Dopamine agonists (pramipexole, ropinirole, rotigotine, apomorphine) Levodopa gel intestinal infusions COMT inhibitors (entacapone, tolcapone, opicapone) MAO-B inhibitors (rasagiline, safinamide) Zonisamide Bilateral STN and GPi stimulation . Dyskinesia (Efficacious) Intestinal infusions Amantadine Bilateral STN and GPi stimulation clozapine Fox et al. Mov Disord March 2018 Modest benefit . MAO-B inhibitors (selegiline, rasagiline, safinamide) Modest benefit
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al
    US 20130253 056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas et al. (43) Pub. Date: Sep. 26, 2013 (54) CONTINUOUS ADMINISTRATION OF (60) Provisional application No. 61/179,511, filed on May LEVODOPA AND/OR DOPA 19, 2009. DECARBOXYLASE INHIBITORS AND COMPOSITIONS FOR SAME Publication Classification (71) Applicant: NEURODERM, LTD., Ness-Ziona (IL) (51) Int. Cl. A63L/216 (2006.01) (72) Inventors: Mara Nemas, Gedera (IL); Oron (52) U.S. Cl. Yacoby-Zeevi, Moshav Bitsaron (IL) CPC .................................... A6 IK3I/216 (2013.01) USPC .......................................................... 514/538 (73) Assignee: Neuroderm, Ltd., Ness-Ziona (IL) (57) ABSTRACT (21) Appl. No.: 13/796,232 Disclosed herein are for example, liquid aqueous composi (22) Filed: Mar 12, 2013 tions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neuro Related U.S. Application Data logical or movement diseases or disorders such as restless leg (63) Continuation-in-part of application No. 12/961,534, syndrome, Parkinson's disease, secondary parkinsonism, filed on Dec. 7, 2010, which is a continuation of appli Huntington's disease, Parkinson's like syndrome, PSP. MSA, cation No. 12/836,130, filed on Jul. 14, 2010, now Pat. ALS, Shy-Drager syndrome, dystonia, and conditions result No. 7,863.336, which is a continuation of application ing from brain injury including carbon monoxide or manga No. 12/781,357, filed on May 17, 2010, now Pat. No. nese intoxication, using Substantially continuous administra 8,193,243. tion of levodopa and/or carbidopa or ester and/or salt thereof.
    [Show full text]
  • Screening of a Composite Library of Clinically Used Drugs and Well
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pharmacol Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2017 November 01. Published in final edited form as: Pharmacol Res. 2016 November ; 113(Pt A): 18–37. doi:10.1016/j.phrs.2016.08.016. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer Nadiya Druzhynaa, Bartosz Szczesnya, Gabor Olaha, Katalin Módisa,b, Antonia Asimakopoulouc,d, Athanasia Pavlidoue, Petra Szoleczkya, Domokos Geröa, Kazunori Yanagia, Gabor Töröa, Isabel López-Garcíaa, Vassilios Myrianthopoulose, Emmanuel Mikrose, John R. Zatarainb, Celia Chaob, Andreas Papapetropoulosd,e, Mark R. Hellmichb,f, and Csaba Szaboa,f,* aDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA bDepartment of Surgery, The University of Texas Medical Branch, Galveston, TX, USA cLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece dCenter of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece eNational and Kapodistrian University of Athens, School of Pharmacy, Athens, Greece fCBS Therapeutics Inc., Galveston, TX, USA Abstract Cystathionine-β-synthase (CBS) has been recently identified as a drug target for several forms of cancer. Currently no
    [Show full text]
  • Gait Analysis in Advanced Parkinson's Disease – Effect of Levodopa And
    ORIGINAL ARTICLE Gait Analysis in Advanced Parkinson’s Disease – Effect of Levodopa and Tolcapone Din-E Shan, Shwn-Jen Lee, Ling-Yi Chao, and Shyh-Ing Yeh ABSTRACT: Objective: To determine the therapeutic effect of levodopa/benserazide and tolcapone on gait in patients with advanced Parkinson’s disease. Methods: Instrumental gait analysis was performed in 38 out of 40 patients with wearing-off phenomenon during a randomized, double-blind, placebo- controlled trial of tolcapone. R e s u l t s : Gait analysis disclosed a significant improvement by levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints. At the end of the study, both the UPDRS motor scores during off-period and the percentage of off time improved significantly using tolcapone. However, gait analysis could not confirm this improvement. With respect to levodopa/benserazide effect, the reduction in rigidity correlated with improved angular excursion of the ankle, whereas the decreased bradykinesia correlated with improved stride length and angular excursion of the hip and knee joints. Conclusion: The results of our gait analysis confirmed that in parkinsonian patients with fluctuating motor symptoms levodopa/benserazide, but not tolcapone, produced a substantial improvement. RÉSUMÉ: Analyse de la démarche chez les patients en phase avancée de la maladie de Parkinson – Effet de la lévodopa et du tolcapone. Objectif: Le but de cette étude était de déterminer l’effet thérapeutique de la lévodopa/bensérazide et du tolcapone sur la démarche, chez les patients en phase avancée de la maladie de Parkinson. Méthodes: Une analyse instrumentale de la démarche a été réalisée chez 38 de 40 patients ayant un phénomène de détérioration de fin de dose pendant un essai randomisé, en double insu, contrôlé par placebo, du tolcapone.
    [Show full text]
  • PSP: Some Answers
    PSP: Some Answers Lawrence I. Golbe, MD Professor of Neurology, Rutgers Robert Wood Johnson Medical School Director of Clinical Affairs and Scientific Advisory Board Chairman, CurePSP October 2017 What is Progressive Supranuclear Palsy (PSP)? Of the approximately five to seven of every 100,000 people in Canada with progressive supranuclear palsy (PSP), few, if any, had ever heard of the disease before their diagnosis. In fact, most patients with PSP report that their family doctors knew nothing about it until a neurologist made the diagnosis. As of now, three of every four people with a diagnosis of PSP could have been diagnosed earlier, if their doctor had suspected it and performed the appropriate examination. However, it is appearing in medical journals more and more often, which will help doctors become familiar with PSP. This pamphlet should help patients and their families do the same. Why has no one heard of PSP? PSP is rare: no one even realized it existed until 1963, when several patients were first described at a national neurology research convention and the disease was given its name. In retrospect, at least 12 cases of PSP had appeared in the medical literature between 1909 and 1962, but because of its resemblance to Parkinson’s, it wasn’t recognized as a distinct disease. The brain under the microscope is almost identical to that of “post-encephalitic parkinsonism,” a common condition in the early 20th century but now nearly extinct, which also made for erroneous diagnoses during that era. Although PSP is slightly more common than the well-known amyotrophic lateral sclerosis (called ALS, or Lou Gehrig’s disease in the U.S.
    [Show full text]
  • Inbrija, INN-Levodopa
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Inbrija 33 mg inhalation powder, hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 42 mg levodopa. Each delivered dose contains 33 mg levodopa. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Inhalation powder, hard capsule. White opaque capsules containing white powder, with “A42” printed in black on the cap of the capsule and two black bands printed on the body of the capsule. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. 4.2 Posology and method of administration Posology Patients should be on a stable levodopa/dopa-decarboxylase inhibitor (e.g. carbidopa or benserazide) regimen before starting Inbrija. Patients selected for treatment with Inbrija should be able to recognize the onset of their 'OFF' symptoms and be capable of preparing the inhaler or else have a responsible care giver able to prepare the inhaler for them when required. Inbrija should be inhaled when symptoms, motor or non-motor, of an OFF period start to return. The recommended dose of Inbrija is 2 hard capsules up to 5 times per day each delivering 33 mg levodopa. The maximum daily dose of Inbrija should not exceed 10 capsules (330 mg). It is not recommended to take more than 2 capsules per OFF period. Exceeding the recommended dose may lead to increased levodopa associated adverse reactions.
    [Show full text]
  • Summary of Drug Limitations Mary C
    RON DESANTIS GOVERNOR SUMMARY OF DRUG LIMITATIONS MARY C. MAYHEW SECRETARY **Medications listed in this document may or may not require a prior authorization. Please view the Preferred Drug List at: http://ahca.myflorida.com/Medicaid/Prescribed_Drug/pharm_thera/fmpdl.shtml** Summary of Drug Limitations Abilify (aripiprazole) 2mg, 5mg, 20mg, 30mg tablets Minimum age = 6; Maximum of 1 tablet per day Abilify (aripiprazole) 10mg, 15mg tablets Minimum age = 6; Maximum of 15mg per day for ages = 6 - 11; Maximum of 30mg per day for ages = 12-17 Maximum of 1 tablet per day Abilify (aripiprazole) Discmelt 10mg, 15mg tabs Minimum age = 6; Maximum of 15mg per day for ages = 6 - 11; Maximum of 30mg per day for ages = 12-17; Maximum of 2 tablets per day Abilify (aripiprazole) 1mg/ml solution Minimum age = 6; Maximum of 15ml per day for ages = 6 - 11; Maximum of 30ml per day for ages = 12-17; Maximum of 30ml per day for ages =/> 18 Abilify Maintena (aripiprazole) syringe/vial Minimum age = 18; Maximum of 1 syringe or vial every 28 days Absorica (isotretinoin) 10mg, 20mg, 25mg,30mg, 35mg, & Minimum age = 12 40mg capsules Abstral (fentanyl citrate) sublingual tablets Minimum age = 18; Maximum of 4 sublingual tablets per day Acanya (benzoyl peroxide/clindamycin)Gel, gel pump Minimum Age= 12 Accolate (zafirlukast) tablets Maximum of 3 tablets per day Aciphex (rabeprazole) 5mg, 10mg sprinkle capsules Minimum age = 1; Maximum age = 11; Maximum of 1 capsule per day Aciphex (rabeprazole) 20mg tablets Minimum age = 1; Maximum of 2 tablets per day Actemra (tocilizumab) 80mg/4ml, 200mg/10ml, Minimum age= 2 400mg/20ml Vials, & 162mg/0.9ml Syringe Actimmune (Interferon Gamma-1b) Maximum of 6ml every 28days Actiq (fentanyl citrate) Lozenges Minimum age = 18; Maximum of 4 lozenges per day Activella (estradiol/norethindrone) tablets Minimum age = 18 Updated 02/28/2019 1 RON DESANTIS GOVERNOR SUMMARY OF DRUG LIMITATIONS MARY C.
    [Show full text]
  • 207145Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207145Orig1s000 OTHER REVIEW(S) CSS Consult: NDA 207,145 Safinamide M E M O R A N D U M Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research * Date: March 8, 2017 To: Billy Dunn, M.D., Director Division of Neurology Products Through: Martin Rusinowitz, M.D., Medical Officer Silvia Calderon, Ph.D., Pharmacologist Controlled Substance Staff From: Alicja Lerner, M.D., Ph.D., Medical Officer Controlled Substance Staff Subject: Erratum-CSS Review of NDA 207,145 dated December 29, 2016 (Author: Lerner, Alicja) AMENDMENT This memorandum corrects an error and changes the title of Table 4, page 14, in the previously submitted CSS review dated Dec 29, 2016. In our prior review, we erroneously listed the subject population reporting the tabulated adverse events as comprising only healthy volunteers (HV). However, as indicated in the revised Table Title, the data derived from Phase 2 and Phase 3 controlled trials. This erratum does not change the conclusions or recommendations in the previous CSS review. Table 4 should read: Table 4. Summary of Selected Abuse Potential Adverse Events from all Completed Safinamide Phase 2 and Phase 3 Controlled Trials for PD – All Pooled Studies (based on the table 11, page 27, 8 factor-analysis). 1 of 2 Reference ID: 4066812 CSS Consult: NDA 207,145 Safinamide Body System Or Organ Class All Safinamide Placebo pool pool N=919 N=1516 (n, %) (n, %) Patients with at least one abuse potential event 230 (15.2)
    [Show full text]
  • 210913Orig1s000 CLINICAL PHARMACOLOGY REVIEW(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210913Orig1s000 CLINICAL PHARMACOLOGY REVIEW(S) Office of Clinical Pharmacology Review NDA Number 212489 Link to EDR \\cdsesub1\evsprod\nda212489 Submission Date 04/26/2019 Submission Type 505(b)(1) NME NDA (Standard Review) Brand Name ONGENTYS Generic Name opicapone Dosage Form/Strength and Capsules: 25 mg and 50 mg Dosing Regimen 50 mg administered orally once daily at bedtime Route of Administration Oral Proposed Indication Adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s Disease experiencing “OFF” episodes Applicant Neurocrine Biosciences, Inc. (NBI) Associated IND IND (b) (4) OCP Review Team Mariam Ahmed, Ph.D. Atul Bhattaram, Ph.D. Sreedharan Sabarinath, Ph.D. OCP Final Signatory Mehul Mehta, Ph.D. 1 Reference ID: 4585182 Table of Contents 1. EXECUTIVE SUMMARY .............................................................................................................................................................. 4 1.1 Recommendations ..................................................................................................................................................... 4 1.2 Post-Marketing Requirements and Commitments ......................................................................................... 6 2. SUMMARY OF CLINICAL PHARMACOLOGY ASSESSMENT ............................................................................................. 6 2.1 Pharmacology and Clinical Pharmacokinetics ..................................................................................................
    [Show full text]